Cereset brain device tested in stressed caregivers of people with dementia
Tests Cereset for heart rate variability and stress in dementia caregivers.
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Where
- Winston-Salem, United StatesSee the site
- Trial code
- Registry title
- Cereset Research for Caregivers
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 16 Jun 2022
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cereset Research
- Record updated
- 1 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who care for someone at least 10 hours per week and have stress, anxiety or sleep problems. The summary describes caregivers of a person living with dementia.
- Age
- 18 Years and older
- Sex
- All
- Disease stage
- Self-reported stress, anxiety or insomnia, with a score at or above a set level on at least one questionnaire: Insomnia Severity Index (ISI, ≥ 8), Perceived Stress Index (PSS, ≥ 14), or GAD-7 (≥ 5).
- Earlier treatment
- No use of the tested technology in the past 3 years. No neuromodulation, neurostimulation, deep brain stimulation, neurofeedback, biofeedback, alpha stim, EMDR or electroconvulsive therapy within the last month.
Main reasons for not taking part
- Known seizure disorder, or suicidal thoughts within the last 3 months
- Hearing loss so severe that tones through ear buds cannot be heard
- Pacemaker, or taking medicines such as beta blockers that affect heart rate variability
- Weight more than 400 pounds (181 kg)
- Currently in another intervention study
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Participants must provide caregiving at least 10 hours per week. This includes all types of caregiving
- participants must be willing to provide informed consent
- participants must be able to comply with basic instructions
- participants must be able to sit comfortably for up to 90 minutes, and attend up to three 60-minute intervention sessions each week during the 4-week intervention period
- participants must self report experiencing symptoms of stress, anxiety, or insomnia and meet threshold scores on one or more self-report inventories of these symptoms (Insomnia Severity Index (ISI, ≥ 8), the Perceived Stress Index (PSS, ≥ 14), or the Generalized Anxiety Disorder 7-item (GAD-7, ≥ 5) scale)
Who cannot take part
- prior use (past 3 years) of the technology being tested
- prior use of neuromodulation, neurostimulation, deep brain stimulation, neurofeedback, biofeedback, alpha stim, Eye Movement Desensitization and Reprocessing (EMDR),or electroconvulsive therapy within the last month
- participants with hearing impairment severe enough that they cannot perceive tones through ear buds
- participants with known seizure disorder, or suicidal thoughts within the last 3 months
- Pace makers and beta blockers that affect the assessment of heart rate variability will also be exclusionary
- participants taking Medications that may affect the assessment of heart rate variability (beta blockers
- participants providing less than 10 hours a week of care to a person
- participants who are unable or unwilling to attend intervention sessions during the planned study period
- participants who are unable or unwilling to provide consent
- participants who are not exhibiting symptoms of stress, anxiety or insomnia
- participants who respond positively to a question about risk for suicide within the last 3 months will be excluded and receive a behavioral health resource list
- participants weighing more than 400 pounds (the weight limit of the chair used during intervention)
- participants currently enrolled in another intervention study
Where in United States
- Wake Forest University Health SciencesWinston-Salem, United StatesContact: Kenzie BrownTaking people
About the trial
What the trial wants to find out
Caregivers experience high levels of prolonged stress that can lead to chronic problems with health, including increased risk of cardiovascular disease that is linked to autonomic dysregulation. Heart rate variability (HRV), measures of autonomic cardiovascular regulation, is decreased (worse) in caregivers. Autonomic function is linked to lateralization in the brain, and emerging neuromodulation methods that target lateralized signals in the brain, like Cereset (CR), may be able to improve heart rate variability. Therefore, this pilot study aims to test whether CR can improve HRV in caregivers of a person living with dementia experiencing stress, anxiety, or insomnia, as well as improve self-report measures of stress, sleep and caregiver burden.
The 2 groups in the trial
- Cereset ResearchExisting treatment, for comparison
This will be the active intervention arm using 4 Cereset (CR) sessions and participants will continue current care.
- ControlSham treatment, for comparison
Participants will have 4 CR sessions of sham control tones and also continue their current care.
Treatment: Cereset Research
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Cereset Research for Caregivers: A Randomized, Controlled Trial
- Plain-language title
- Cereset brain device tested in stressed caregivers of people with dementiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 1 June 2026